Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 2/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16279057 | 1.00 | MAPT (0.62) | MAPTSYKHTTKLK7KLK5 | |
| SCHEMBL1022850 | 0.97 | MAPT (0.66) | MAPTSYKHTTKLK7KLK5 | |
| SCHEMBL1021955 | 0.96 | SYK (0.64) | MAPTSYKHTTKLK7KLK5 | |
| SCHEMBL6372820 | 0.93 | SYK (0.60) | MAPTSYKHTTKLK7KLK5 | |
| SCHEMBL6372825 | 0.93 | SYK (0.60) | MAPTSYKHTTKLK7KLK5 | |
| SCHEMBL20556374 | 0.93 | SYK (0.63) | MAPTSYKHTTKLK7KLK5 | |
| SCHEMBL20556328 | 0.93 | SYK (0.63) | MAPTSYKHTTKLK7KLK5 | |
| SCHEMBL19345775 | 0.93 | SYK (0.63) | MAPTSYKHTTKLK7KLK5 | |
| SCHEMBL4883784 | 0.90 | MAPT (0.61) | MAPTSYKHTTKLK7KLK5 | |
| SCHEMBL21789935 | 0.90 | MAPT (0.63) | MAPTSYKHTTKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371274-B2 | Compound having read-through activity | THE UNIVERSITY OF TOKYO (JP) | 2016-06-21 | — | — | US | disclosed |
| US-9371274-B2 | Compound having read-through activity | THE UNIVERSITY OF TOKYO (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20140364642-A1 | COMPOUND HAVING READ-THROUGH ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20140364642-A1 | COMPOUND HAVING READ-THROUGH ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2014-12-11 | — | — | US | disclosed |
| EP-1797110-B1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-20080275018-A1 | ANTIBACTERIAL AMIDE-MACROCYCLES V | AICURIS GMBH & CO. KG (DE) | 2008-11-06 | — | — | US | disclosed |
| US-7446102-B2 | Antibacterial amide macrocycles IV | AICURIS GMBH & CO. KG (DE) | 2008-11-04 | — | — | US | disclosed |
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO. KG (DE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| EP-1797110-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AiCuris GmbH & Co. KG (DE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006034786-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | AICURIS GMBH & CO.KG (DE) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076745-A1 | ANTIBACTERIAL AMIDE MACROCYCLES IV | NOD2, AAAS, AADAC | MAPT 4356/4885SYK 3060/4885HTT 1796/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | MAPT 2849/4885SYK 3178/4885HTT 409/4885 |
| US-20080275018-A1 | ANTIBACTERIAL AMIDE-MACROCYCLES V | ARG1, HRH3, H1-0 | MAPT 4840/4885SYK 2058/4885HTT 1449/4885 |
| US-20140364642-A1 | COMPOUND HAVING READ-THROUGH ACTIVITY | UPF1, NUDT21, GBA2 | MAPT 3268/4885SYK 4808/4885HTT 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.